UT Health San Antonio registers Phase 1/2 trial of Corcept's relacorilant in T2D with cortisol exces
A new study will test whether relacorilant improves glucose control in patients with difficult-to-control type 2 diabetes and confirmed cortisol excess, with Corcept Therapeutics as collaborator.
One new trial involving Corcept Therapeutics was registered this week.
- A Phase 1/2 study titled "Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secretion" (NCT07925801) is sponsored by The University of Texas Health Science Center at San Antonio, with Corcept Therapeutics listed as a collaborator. The study aims to investigate the mechanisms by which glucocorticoid receptor antagonism with relacorilant improves glucose homeostasis in patients with difficult-to-control type 2 diabetes and confirmed endogenous hypercortisolism.1 The trial is not yet recruiting, with an estimated enrollment of 34 participants1 and a primary outcome of HbA1c levels measured from baseline to 24 weeks.1 Estimated start is 2026-12-01.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.